Mark Slifka

Professor

  • 7164 Citations
  • 43 h-Index
1976 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Mark Slifka is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles
Virus Diseases Medicine & Life Sciences
T-Lymphocytes Medicine & Life Sciences
Viruses Medicine & Life Sciences
Vaccination Medicine & Life Sciences
Vaccines Medicine & Life Sciences
Immunity Medicine & Life Sciences
Lymphocytic choriomeningitis virus Medicine & Life Sciences
Smallpox Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1976 2017

Dengue Vaccines
Dengue Virus
Inactivated Vaccines
Vaccines
Attenuated Vaccines

Pacific NorthWest Regional Center of Excellence (PNWRCE)

Streblow, D., Slifka, M., McWeeney, S., Axthelm, M., Moses, A., Nelson, J., Baric, R., Landfear, S., Nikolich-Zugich, J., Barklis, E., Gale, M., Katze, M., Kawaoka, Y., Bevan, M., Smith, R., Maizels, N., Frueh, K., Labeaud, A. D., Ryman, K., Chanda, S., Galloway, D. A. & Fruh, K.

National Institutes of Health

4/20/092/28/15

Project: Research project

Northwestern United States
National Institute of Allergy and Infectious Diseases (U.S.)
Vulnerable Populations
Research
Vaccines
West Nile Virus Vaccines
West Nile virus
Virus Diseases
Vaccines
National Institute of Allergy and Infectious Diseases (U.S.)

Research Output 1995 2019

  • 7164 Citations
  • 43 h-Index
  • 128 Article
  • 2 Review article
  • 1 Letter
1 Citation (Scopus)

Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine

Quintel, B. K., Thomas, A., Poer DeRaad, D. E., Slifka, M. & Amanna, I. J., Jan 1 2019, (Accepted/In press) In : Vaccine.

Research output: Contribution to journalArticle

West Nile Virus Vaccines
West Nile virus
Inactivated Vaccines
Virus Inactivation
Vaccines
1 Citation (Scopus)

An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults

Woods, C. W., Sanchez, A. M., Swamy, G. K., McClain, M. T., Harrington, L., Freeman, D., Poore, E. A., Slifka, D. K., Poer DeRaad, D. E., Amanna, I. J., Slifka, M., Cai, S., Shahamatdar, V., Wierzbicki, M. R., Amegashie, C. & Walter, E. B., Jan 1 2019, (Accepted/In press) In : Vaccine.

Research output: Contribution to journalArticle

West Nile Virus Vaccines
West Nile virus
Inactivated Vaccines
placebos
Placebos
1 Citation (Scopus)

Maturation of the infant rhesus macaque gut microbiome and its role in the development of diarrheal disease

Rhoades, N., Barr, T., Hendrickson, S., Prongay, K., Haertel, A., Gill, L., Garzel, L., Whiteson, K., Slifka, M. & Messaoudi, I., Aug 26 2019, In : Genome biology. 20, 1, 173.

Research output: Contribution to journalArticle

Open Access
diarrheal disease
Macaca mulatta
maturation
diarrhea
digestive system

Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses

Slifka, M. & Amanna, I. J., Jan 1 2019, In : Frontiers in immunology. 10, 1 p.

Research output: Contribution to journalReview article

Open Access
Antibody Formation
Immunity
Vaccines
Plasma Cells
Vaccination
3 Citations (Scopus)

Dengue Serostatus and Dengue Vaccine Safety and Efficacy

Slifka, M. & Amanna, I. J., Nov 15 2018, In : The New England journal of medicine. 379, 20, 1 p.

Research output: Contribution to journalLetter

Dengue Vaccines
Dengue
Safety